In the annual Research Round Up series, Cancer.Net Associate Editors answer the question, “What was the most exciting or practice-changing research in your field presented at the 2021 ASCO Annual Meeting?” In this episode, 3 experts discuss new research from the meeting in lung cancer, breast cancer, and sarcoma.
Listen below, and subscribe to Cancer.Net Podcasts wherever you listen to podcasts for new episodes in this series throughout the summer.
Research on new treatments for non-small cell lung cancer
Dr. Charu Aggarwal, the 2021 Cancer.Net Associate Editor for Lung Cancer, discusses results from 3 studies evaluating new treatments for non-small cell lung cancer (NSCLC). First, she discusses the phase 2 CodeBreaK 100 clinical trial, which evaluated whether using the targeted therapy sotorasib (Lumakras) to treat people with metastatic non-small cell lung cancer with a KRAS G12C mutation shrank the tumors. [2:35] Next, she discusses a 5-year update from the phase 3 PACIFIC clinical trial on whether treating people with stage III (3) non-small cell lung cancer using the immunotherapy durvalumab (Imfinzi) following chemotherapy with radiation therapy helped them live longer. [4:46] Finally, she discusses the phase 3 Impower010 clinical trial, which tested whether treating people with early-stage non-small cell lung cancer with the immunotherapy atezolizumab (Tecentriq) following surgery and chemotherapy reduced their risk of recurrence, or the cancer coming back. [6:46]
Advances in treating early-stage breast cancer
Dr. Lynn Henry, the 2021 Cancer.Net Associate Editor for Breast Cancer, discusses results from 2 studies in breast cancer, the first of which was the phase 3 OlympiA clinical trial. In this study, researchers were evaluating whether treating people with a BRCA mutation and early-stage, HER2-negative breast cancer using olaparib (Lynparza), a type of targeted therapy called a PARP inhibitor, decreased the likelihood of the cancer returning. [10:40] Dr. Henry also discusses the final results from the phase 3 PROMISE-GIM6 clinical trial. Sometimes, ovarian suppression is given to preserve a patient’s ability to have children, or fertility, after treatment with chemotherapy ends. This trial was observing whether ovarian suppression combined with chemotherapy impacted a patient’s risk of recurrence. [12:47]
Research highlights for the treatment of sarcoma
Dr. Vicki Keedy, the 2021 Cancer.Net Associate Editor for Sarcoma, discusses results from 2 studies testing new treatments for sarcoma. The first study, the phase 2 SPEARHEAD-1 clinical trial, looked at whether treating people with metastatic synovial sarcoma or myxoid/round cell liposarcoma using afami-cel, a type of immunotherapy called T-cell receptor therapy, shrank the tumors. [15:38] The second study evaluated whether treating people with metastatic synovial sarcoma using catequentinib, a type of targeted therapy called a tyrosine kinase inhibitor, slowed down their tumor growth compared to treatment with the chemotherapy dacarbazine (DTIC). [18:42]
Disclosure information for this podcast’s speakers can be found in their individual biographies, which are linked to in the paragraphs above.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.
Cancer.Net podcasts are edited for length and content.